Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 5/20 | 0.77 |
| ▸ | PPARD | Q03181 | 5/20 | 0.77 |
| ▸ | PPARA | Q07869 | 5/20 | 0.77 |
| ▸ | F7 | P08709 | 5/20 | 0.77 |
| ▸ | F3 | P13726 | 5/20 | 0.77 |
| ▸ | TERT | O14746 | 3/20 | 0.77 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.77 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.77 |
| ▸ | FABP4 | P15090 | 3/20 | 0.77 |
| ▸ | TOP1 | P11387 | 3/20 | 0.77 |
| ▸ | MAPT | P10636 | 2/20 | 0.77 |
| ▸ | BLM | P54132 | 2/20 | 0.77 |
| ▸ | LMNA | P02545 | 2/20 | 0.77 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.77 |
| ▸ | DUSP3 | P51452 | 2/20 | 0.77 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.77 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.77 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.77 |
| ▸ | SIRT6 | Q8N6T7 | 2/20 | 0.77 |
| ▸ | PTPN7 | P35236 | 2/20 | 0.77 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Glycerin SCHEMBL10798920 | 1.00 | PPARG (0.77) | PPARGPPARDPPARAF7F3 | |
| Oleic Acid SCHEMBL5176449 | 1.00 | PPARG (0.77) | PPARGPPARDPPARAF7F3 | |
| Glycerin SCHEMBL10796527 | 1.00 | PPARG (0.77) | PPARGPPARDPPARAF7F3 | |
| Oleic Acid SCHEMBL6574521 | 1.00 | PPARG (0.77) | PPARGPPARDPPARAF7F3 | |
| Oleic Acid SCHEMBL6002519 | 1.00 | PPARG (0.77) | PPARGPPARDPPARAF7F3 | |
| Oleic Acid SCHEMBL8848511 | 1.00 | PPARG (0.77) | PPARGPPARDPPARAF7F3 | |
| Erucic Acid SCHEMBL25405469 | 1.00 | PPARG (0.77) | PPARGPPARDPPARAF7F3 | |
| Oleic Acid SCHEMBL15049128 | 1.00 | PPARG (0.77) | PPARGPPARDPPARAF7F3 | |
| Oleic Acid SCHEMBL7931966 | 1.00 | PPARG (0.77) | PPARGPPARDPPARAF7F3 | |
| Oleic Acid SCHEMBL11276244 | 1.00 | PPARG (0.77) | PPARGPPARDPPARAF7F3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3204358-B1 | CO-CRYSTALS OF MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMA (US) | 2018-09-19 | — | — | EP | claimed |
| EP-3204358-A1 | CO-CRYSTALS OF MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | Vertex Pharmaceuticals Incorporated (US) | 2017-08-16 | — | — | EP | claimed |
| US-9701639-B2 | Co-crystals of modulators of cystic fibrosis transmembrane conductance regulator | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2017-07-11 | — | — | US | claimed |
| WO-2016057730-A1 | CO-CRYSTALS OF MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | STROHMEIER MARK (US) | 2016-04-14 | — | — | WO | claimed |
| US-20160096807-A1 | CO-CRYSTALS OF MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2016-04-07 | — | — | US | claimed |
| EP-3204358-B1 | CO-CRYSTALS OF MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMA (US) | 2018-09-19 | — | — | EP | disclosed |
| EP-3204358-A1 | CO-CRYSTALS OF MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | Vertex Pharmaceuticals Incorporated (US) | 2017-08-16 | — | — | EP | disclosed |
| US-9701639-B2 | Co-crystals of modulators of cystic fibrosis transmembrane conductance regulator | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2017-07-11 | — | — | US | disclosed |
| US-9345991-B2 | Defoaming agent | SAN NOPCO LTD. (JP) | 2016-05-24 | — | — | US | disclosed |
| WO-2016057730-A1 | CO-CRYSTALS OF MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | STROHMEIER MARK (US) | 2016-04-14 | — | — | WO | disclosed |
| US-20160096807-A1 | CO-CRYSTALS OF MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2016-04-07 | — | — | US | disclosed |
| CN-104905194-A | Processing technology of preserved kale head packed in glass bottle | HUBEI YUANYEFENG FOOD CO LTD | 2015-09-16 | — | — | CN | disclosed |
| US-20140100293-A1 | DEFOAMING AGENT | SAN NOPCO LTD. (JP) | 2014-04-10 | — | — | US | disclosed |
| EP-2367548-B1 | Medical food composition for treating neurodegenerative diseases | SOFEDUS S R L (IT) | 2013-08-07 | — | — | EP | disclosed |
| EP-2367548-A1 | MEDICAL DIETARY COMPOSITION FOR TREATING NEURODEGENERATIVE DISEASES | Sofedus S.r.l. (IT) | 2011-09-28 | — | — | EP | disclosed |
| WO-2010069915-A1 | MEDICAL DIETARY COMPOSITION FOR TREATING NEURODEGENERATIVE DISEASES | SOFEDUS S.R.L. (IT) | 2010-06-24 | — | — | WO | disclosed |
| US-20030091526-A1 | Treatment of hair by addition of exogenous enzymes, alcohols and acids or triglycerides | L'OREAL (FR) | 2003-05-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160096807-A1 | CO-CRYSTALS OF MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, CLIC1, CLIC4 | PPARG 1915/4885PPARD 2156/4885PPARA 2504/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.